- Home
- INSM vs FWONK Comparison
INSM vs FWONK Comparison
Compare INSM & FWONK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FWONK
- Stock Information
- Founded
- INSM 1988
- FWONK 1950
- Country
- INSM United States
- FWONK United States
- Employees
- INSM N/A
- FWONK N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FWONK Broadcasting
- Sector
- INSM Health Care
- FWONK Industrials
- Exchange
- INSM Nasdaq
- FWONK Nasdaq
- Market Cap
- INSM 26.0B
- FWONK 25.3B
- IPO Year
- INSM 2000
- FWONK N/A
- Fundamental
- Price
- INSM $127.80
- FWONK $99.43
- Analyst Decision
- INSM Strong Buy
- FWONK Buy
- Analyst Count
- INSM 17
- FWONK 9
- Target Price
- INSM $137.40
- FWONK $108.33
- AVG Volume (30 Days)
- INSM 3.0M
- FWONK 1.1M
- Earning Date
- INSM 08-07-2025
- FWONK 08-07-2025
- Dividend Yield
- INSM N/A
- FWONK N/A
- EPS Growth
- INSM N/A
- FWONK N/A
- EPS
- INSM N/A
- FWONK 0.08
- Revenue
- INSM $398,105,000.00
- FWONK $3,860,000,000.00
- Revenue This Year
- INSM $28.23
- FWONK $17.41
- Revenue Next Year
- INSM $119.99
- FWONK $11.26
- P/E Ratio
- INSM N/A
- FWONK $94.59
- Revenue Growth
- INSM 21.15
- FWONK 4.55
- 52 Week Low
- INSM $60.40
- FWONK $74.34
- 52 Week High
- INSM $128.48
- FWONK $106.26
- Technical
- Relative Strength Index (RSI)
- INSM 85.01
- FWONK 48.89
- Support Level
- INSM $106.54
- FWONK $94.57
- Resistance Level
- INSM $128.48
- FWONK $100.12
- Average True Range (ATR)
- INSM 4.11
- FWONK 2.38
- MACD
- INSM 1.68
- FWONK -0.10
- Stochastic Oscillator
- INSM 97.41
- FWONK 56.44
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.